Pancreatic Cancer: Addition of Eryaspase to Chemotherapy Versus Chemotherapy AloneResearch Question:
Does the the addition of eryaspase to chemotherapy improve patient health compared
to chemotherapy alone?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The drug, Eryaspase, is made of L-asparaginase placed inside donor-derived red blood
cells. It is designed to target the modified asparagine and glutamine metabolism of
cancer cells. This is an open-label, multicenter, randomized, Phase 3 study in patients
with ductal adenocarcinoma of the pancreas (pancreatic cancer) who have failed only
one prior line of anti-cancer therapy.
Study Reference #: IGIP19008
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Chris LeFeber
Phone: (585) 275-0407
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search